BioCentury
ARTICLE | Finance

Brawnier for deals

HBM wants more expertise on Basilea board to strengthen partnering talks

October 10, 2011 7:00 AM UTC

HBM BioVentures Ltd.'s proposal to expand the board of Basilea Pharmaceutica AG (SIX:BSLN) signals that the Swiss biotech's largest shareholder hopes partnerships will accompany the clinical data expected over the next year.

HBM CEO Andreas Wicki said Basilea has a significant amount of upcoming clinical data, including U.S. Phase III results around year end for Toctino alitretinoin to treat severe chronic hand eczema...